

Item 9.01. Financial Statements and Exhibits.

The following document extends the period of the SWO until November 17, 2008. It is being filed with this Form 8-K solely because it was inadvertently omitted from our Form 10-Q filed on October 31, 2008. The total contract amount remains unchanged (\$102,661,429). The contract completion date remains unchanged (December 31, 2010).

Exhibit

Number

Description

10.1	Amendment of Solicitation/Modification of Contract.
------	---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioCryst Pharmaceuticals, Inc.

Date: November 7, 2008

By: /s/ Michael A. Darwin

Name: Michael A. Darwin

Title: Vice President Finance

EXHIBIT INDEX

Exhibit Number	Description
10.1	Amendment of Solicitation/Modification of Contract.